Actively Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-04-17
400
Participants Needed
1
Research Sites
145 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.
CONDITIONS
Official Title
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation with written informed consent
- Age between 18 and 75 years, no gender restriction
- Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
- Life expectancy of at least 3 months
- Pathological diagnosis of non-small cell lung cancer
- Ability to provide fresh or archived tumor tissue
- At least one measurable tumor lesion according to RECIST v1.1
- Adequate organ function
- Use of contraception during the trial and negative pregnancy test within 7 days before first dose for women of childbearing potential
You will not qualify if you...
- History or symptoms of meningeal or central nervous system metastasis
- Previous or current other malignancies
- Untreated spinal cord compression
- Uncontrolled tumor-related pain
- Major surgery within 28 days or minor surgery within 7 days before initial dosing
- Treatment with other investigational drugs within 4 weeks prior to study treatment
- Unresolved toxicities greater than grade 2 from prior anticancer therapy
- Poorly controlled or severe cardiovascular disease
- Active hepatitis B or hepatitis C infection
- History of immunodeficiency
- Severe infection within 30 days before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030
Actively Recruiting
Research Team
Y
Yijun Jia
CONTACT
T
Tingting Lei
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here